Benjamin W. Weston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin W. Weston has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Bernard S. Black
Pritzker School of Law, Northwestern University, Chicago, IL 60611, USA
11 shared publications - Qian Luo
Department of Health Policy and Management, Milken Institute School of Public Health, George Washington University, Washington, DC 20053, USA
8 shared publications - Andy Ye Yuan
University of Florida , Gainesville, FL
6 shared publications Jeff Whittle
5 shared publications- John R. Meurer
Medical College of Wisconsin
5 shared publications - Sadia Farzana
Pritzker School of Law, Northwestern University, Chicago, IL 60611, USA
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in Resuscitation
- Vol. 229
Ventilation monitoring in out-of-hospital cardiac arrest care
- 29 October 2026
- Published by Elsevier in Resuscitation
- Vol. 229
Open AccessVentilation monitoring in out-of-hospital cardiac arrest care
- Open Access
- 25 August 2026
- Published by Elsevier in SSRN Electronic Journal
Supplementary Material for "Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana"
This Supplementary Material provides additional results and methods details for Farzana et al. (2026), Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana.
- 25 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSupplementary Material for "Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana"
This Supplementary Material provides additional results and methods details for Farzana et al. (2026), Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana.
- Open Access
Pfizer Versus Moderna COVID-19 Vaccine Effectiveness Against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana
Objective: It is commonly believed in the public health community that the mRNA vaccines from Pfizer and Moderna were broadly similar in preventing COVID-19 mortality, with perhaps a small advantage for Moderna. We revisit this question, using a research design that controls for healthy-vaccinee bias. Methods: We studied deaths among persons aged 15 years or greater from January 2021 through December 2022 in Indiana, linked to vaccination records, using an outcome measure, namely COVID-19 Excess Mortality Percentage (CEMP), which uses non-COVID natural mortality to control for HVB. Results: We find both large healthy-vaccinee bias for both vaccines, and larger bias for Pfizervaccinees: Pfizer recipients were healthier and thus would have faced lower COVID-19 mortality without vaccination. For ages 60+, we find almost 50% higher COVID-19 remaining mortality risk (RMR) for Pfizer vaccinees receiving primary vaccination over a “core period” from 2Q2021 through 1Q2022: the average Pfizer/Moderna RMR ratio was 1.49. For ages 15–59, this ratio was 1.25, but was not statistically significant. For booster dose for ages 60+, the average Pfizer/Moderna RMR ratio was 1.34. For 2Q2022 through 4Q2022, after the major Omicron wave, we find much lower vaccine effectiveness and no significant Pfizer–Moderna difference. Conclusions: During the period with both good vaccine availability and high COVID-19 mortality (2Q-2021–1Q2022), the Moderna vaccine was associated with lower COVID-19 mortality, relative to the Pfizer vaccine. A possible explanation is the higher Moderna dose (100 μg vs. 30 for Pfizer). After that period, a high percentage of the population had natural immunity from prior COVID-19 infection; we find only small mortality gains from vaccination, with no significant Pfizer–Moderna difference. Policy Implications: Controlling for healthy-vaccinee bias, Moderna was associated with lower COVID-19 mortality, relative to Pfizer. This difference was not known in real-time due to the failure of the available studies to address healthy-vaccinee bias. Controlling for such bias is vital when making vaccination policy.
Open AccessPfizer Versus Moderna COVID-19 Vaccine Effectiveness Against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana
Objective: It is commonly believed in the public health community that the mRNA vaccines from Pfizer and Moderna were broadly similar in preventing COVID-19 mortality, with perhaps a small advantage for Moderna. We revisit this question, using a research design that controls for healthy-vaccinee bias. Methods: We studied deaths among persons aged 15 years or greater from January 2021 through December 2022 in Indiana, linked to vaccination records, using an outcome measure, namely COVID-19 Excess Mortality Percentage (CEMP), which uses non-COVID natural mortality to control for HVB. Results: We find both large healthy-vaccinee bias for both vaccines, and larger bias for Pfizervaccinees: Pfizer recipients were healthier and thus would have faced lower COVID-19 mortality without vaccination. For ages 60+, we find almost 50% higher COVID-19 remaining mortality risk (RMR) for Pfizer vaccinees receiving primary vaccination over a “core period” from 2Q2021 through 1Q2022: the average Pfizer/Moderna RMR ratio was 1.49. For ages 15–59, this ratio was 1.25, but was not statistically significant. For booster dose for ages 60+, the average Pfizer/Moderna RMR ratio was 1.34. For 2Q2022 through 4Q2022, after the major Omicron wave, we find much lower vaccine effectiveness and no significant Pfizer–Moderna difference. Conclusions: During the period with both good vaccine availability and high COVID-19 mortality (2Q-2021–1Q2022), the Moderna vaccine was associated with lower COVID-19 mortality, relative to the Pfizer vaccine. A possible explanation is the higher Moderna dose (100 μg vs. 30 for Pfizer). After that period, a high percentage of the population had natural immunity from prior COVID-19 infection; we find only small mortality gains from vaccination, with no significant Pfizer–Moderna difference. Policy Implications: Controlling for healthy-vaccinee bias, Moderna was associated with lower COVID-19 mortality, relative to Pfizer. This difference was not known in real-time due to the failure of the available studies to address healthy-vaccinee bias. Controlling for such bias is vital when making vaccination policy.
- 2 August 2026
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 110, 34-37
Paramedic perspectives on prehospital buprenorphine: A qualitative case study of implementation in emergency medical services
- 2 August 2026
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 110, 34-37
Paramedic perspectives on prehospital buprenorphine: A qualitative case study of implementation in emergency medical services
- 13 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2684-2694
Life-expectancy loss during the COVID-19 pandemic: decomposition using individual-level mortality data
We study life expectancy loss (LEL) from the COVID-19 pandemic in the United States from March 2020 through April 2023. We use individual-level death-certificate data and the cohort-based approach to life expectancy. We also examine how LEL varies with age, gender, race/ethnicity, and county-level socioeconomic status (county-SES). The United States recorded 983 000 COVID-19 deaths. The COVID-19 mortality rate (the fraction of the population who died of COVID-19) was 0.30%. An upper bound estimate of years of life lost per person (YLL) is 14.6 years (thus population loss of 14.32 million life-years). Estimated LEL based on this YLL estimate is 0.043 years (16 days). However, LEL rose rapidly with age averaging 8 weeks for ages 75+. LEL was substantially higher for Native Americans, Blacks, and Hispanics than for Whites at all ages, but lower for Asians. LEL also increased as county-SES decreased. Our cohort-based LEL estimates are a small fraction of period-based estimates during the pandemic, which were based on mortality in a particular year and assumed the pandemic would continue indefinitely with no change in severity. Using current life expectancies, cohort-based LEL for the COVID-19 pandemic was a fraction of LEL for the 1918 influenza pandemic (14 weeks), but well above 3 recent, severe influenza seasons (average of 0.12 weeks).
- 13 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2684-2694
Life-expectancy loss during the COVID-19 pandemic: decomposition using individual-level mortality data
We study life expectancy loss (LEL) from the COVID-19 pandemic in the United States from March 2020 through April 2023. We use individual-level death-certificate data and the cohort-based approach to life expectancy. We also examine how LEL varies with age, gender, race/ethnicity, and county-level socioeconomic status (county-SES). The United States recorded 983 000 COVID-19 deaths. The COVID-19 mortality rate (the fraction of the population who died of COVID-19) was 0.30%. An upper bound estimate of years of life lost per person (YLL) is 14.6 years (thus population loss of 14.32 million life-years). Estimated LEL based on this YLL estimate is 0.043 years (16 days). However, LEL rose rapidly with age averaging 8 weeks for ages 75+. LEL was substantially higher for Native Americans, Blacks, and Hispanics than for Whites at all ages, but lower for Asians. LEL also increased as county-SES decreased. Our cohort-based LEL estimates are a small fraction of period-based estimates during the pandemic, which were based on mortality in a particular year and assumed the pandemic would continue indefinitely with no change in severity. Using current life expectancies, cohort-based LEL for the COVID-19 pandemic was a fraction of LEL for the 1918 influenza pandemic (14 weeks), but well above 3 recent, severe influenza seasons (average of 0.12 weeks).
- Open Access
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
Appendix for: COVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved
This Appendix contains additional details on the data sources, data cleaning, simulation procedure and additional results for Luo et al. (2026), COVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved, http://ssrn.com/abstract=6841624.
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAppendix for: COVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved
This Appendix contains additional details on the data sources, data cleaning, simulation procedure and additional results for Luo et al. (2026), COVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved, http://ssrn.com/abstract=6841624.
- Open Access
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
COVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved
COVID-19 killed millions of people worldwide, but rapid vaccine development saved millions of lives. We model lives saved in the U.S., by age range, under three alternative scenarios: (i) no vaccination; (ii) full vaccination (95% vaccination of all persons); and (iii) a faster booster scenario, with 95% booster uptake among those with primary vaccination plus booster update speed matching the actual speed achieved for primary vaccination. There were 983,000 COVID-19 deaths in the U.S. over the pandemic period (March 2020-April 2023); this would have been 1,787,000 with no vaccination (804,000 lives saved). Full vaccination would have saved 62,000 additional lives and faster booster uptake would have saved another 47,000 lives. Mean life-years lost per decedent were 14.70; total life-years saved by vaccination were 14.5 million; full vaccination and faster booster uptake would have saved an additional 1.7 million and 649,000 life years, respectively. Most lives saved from vaccination, or deaths not saved due to lack of full vaccination, were for the middle-aged and elderly, but the percentage of preventable COVID-19 deaths due to partial vaccine uptake was largest for younger persons, due to lower vaccination rates. The effect of partial uptake on life-years lost was largest for the middle aged.
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCOVID-19 Vaccination: Actual and Potential Lives and Life-Years Saved
COVID-19 killed millions of people worldwide, but rapid vaccine development saved millions of lives. We model lives saved in the U.S., by age range, under three alternative scenarios: (i) no vaccination; (ii) full vaccination (95% vaccination of all persons); and (iii) a faster booster scenario, with 95% booster uptake among those with primary vaccination plus booster update speed matching the actual speed achieved for primary vaccination. There were 983,000 COVID-19 deaths in the U.S. over the pandemic period (March 2020-April 2023); this would have been 1,787,000 with no vaccination (804,000 lives saved). Full vaccination would have saved 62,000 additional lives and faster booster uptake would have saved another 47,000 lives. Mean life-years lost per decedent were 14.70; total life-years saved by vaccination were 14.5 million; full vaccination and faster booster uptake would have saved an additional 1.7 million and 649,000 life years, respectively. Most lives saved from vaccination, or deaths not saved due to lack of full vaccination, were for the middle-aged and elderly, but the percentage of preventable COVID-19 deaths due to partial vaccine uptake was largest for younger persons, due to lower vaccination rates. The effect of partial uptake on life-years lost was largest for the middle aged.
- Open Access
- 23 April 2026
- Published by Oxford University Press (OUP) in AJE Advances: Research in Epidemiology
Measuring Maternal Mortality and Mortality Disparities: A Health-Adjusted Approach
Racial and ethnic disparities in maternal mortality are well known, especially the higher rates for Black and Native American women. However, the underlying causes remain unclear. These disparities may stem from disparities in background health across groups or from factors specific to childbirth and maternal care. We examine maternal mortality disparities using a novel method that controls for population differences in overall health. Unadjusted maternal mortality rate (MMR) ratios for Black, Asian, Hispanic, and Native American women relative to White women, measured over 2010-2022, excluding COVID-19 deaths, are 2.7, 0.91, 0.88, and 2.58. In contrast, adjusted ratios are 1.83, 1.31, 1.27, and 1.24, respectively. Poor background health contributes to the high maternal mortality risk among Black and Native American women, while better underlying health among Asian and Hispanic women masks their elevated adjusted maternal mortality risk. We also document substantial cross-state heterogeneity in adjusted MMRs and racial/ethnic disparities in these rates. In some states, minority women face substantially higher maternal mortality risks relative to White women, while in others—notably California—health-adjusted disparities are small.
- 23 April 2026
- Published by Oxford University Press (OUP) in AJE Advances: Research in Epidemiology
Open AccessMeasuring Maternal Mortality and Mortality Disparities: A Health-Adjusted Approach
Racial and ethnic disparities in maternal mortality are well known, especially the higher rates for Black and Native American women. However, the underlying causes remain unclear. These disparities may stem from disparities in background health across groups or from factors specific to childbirth and maternal care. We examine maternal mortality disparities using a novel method that controls for population differences in overall health. Unadjusted maternal mortality rate (MMR) ratios for Black, Asian, Hispanic, and Native American women relative to White women, measured over 2010-2022, excluding COVID-19 deaths, are 2.7, 0.91, 0.88, and 2.58. In contrast, adjusted ratios are 1.83, 1.31, 1.27, and 1.24, respectively. Poor background health contributes to the high maternal mortality risk among Black and Native American women, while better underlying health among Asian and Hispanic women masks their elevated adjusted maternal mortality risk. We also document substantial cross-state heterogeneity in adjusted MMRs and racial/ethnic disparities in these rates. In some states, minority women face substantially higher maternal mortality risks relative to White women, while in others—notably California—health-adjusted disparities are small.
- Open Access
COVID-19 Vaccine Effectiveness Against Mortality in the Omicron Period: Evidence from Linked Mortality and Vaccination Records
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.
Open AccessCOVID-19 Vaccine Effectiveness Against Mortality in the Omicron Period: Evidence from Linked Mortality and Vaccination Records
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.